{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:01:10Z","timestamp":1793386870591,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013401","name":"Ovarian Cancer Research Fund Alliance","doi-asserted-by":"publisher","award":["CRDG-2023-3-1001"],"award-info":[{"award-number":["CRDG-2023-3-1001"]}],"id":[{"id":"10.13039\/100013401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA248565"],"award-info":[{"award-number":["R37CA248565"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK125263"],"award-info":[{"award-number":["R01DK125263"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Andrew McDonough B+ Foundation (KAS) Blavatnik Institute at Harvard"},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Platelets are short-lived anucleate cells essential for primary hemostasis and recognized for their functions in thrombosis, immunity, antimicrobial defense, neurodegeneration, as well as cancer growth and metastasis. Their brief lifespan in circulation is controlled by the removal of sialic acid residues from the platelet surface (desialylation) and also the mitochondrial apoptosis pathway, with high expression of the anti-apoptotic protein BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    being required for platelet survival. This dependence on BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    has prevented the clinical deployment of recently developed small molecule inhibitors of BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    , which have promising activity in solid as well as liquid cancers but cause on-target thrombocytopenia. Here, we investigate the functional relationship between platelet desialylation and apoptosis to determine how cross-talk between these mechanisms may impact platelet lifespan. We find that platelets progressively lose sialic acid residues and become more primed for apoptosis while in circulation, resulting in aged platelets that are desialylated and highly prone to undergoing apoptosis. In addition, platelet desialylation via endogenous or exogenous factors directly increases their BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    dependence and accelerates apoptosis, which can be reversed by treatment with the sialidase inhibitor DANA (2,3-dehydro-2-deoxy-N-acetylneuraminic acid). Notably, young platelets recently released into circulation are less primed for apoptosis and less dependent on BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    for survival. Consistent with these changes in priming, platelets aged in vitro exhibit increasing expression of multiple pro-apoptotic proteins including BIM, BAK and PUMA along with increasing cleaved caspase 3. Leveraging the lower BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    dependence of young platelets, stimulation of de novo platelet production with the thrombopoietin receptor agonist romiplostim prevents BH3 mimetic-induced thrombocytopenia in vivo and may prevent severe platelet loss in patients treated with BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08205-8","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:22:29Z","timestamp":1767882149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Platelet aging and desialylation increase apoptotic priming and BCL-XL dependence"],"prefix":"10.1038","volume":"17","author":[{"given":"Renata","family":"Grozovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-5913","authenticated-orcid":false,"given":"Cameron S.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3263-0843","authenticated-orcid":false,"given":"Xingping","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-9786","authenticated-orcid":false,"given":"Johan","family":"Spetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-5085","authenticated-orcid":false,"given":"Kristopher A.","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"8205_CR1","doi-asserted-by":"crossref","unstructured":"Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematol Am Soc Hematol Educ Program. 2009;1:47\u201352.","DOI":"10.1182\/asheducation-2009.1.147"},{"key":"8205_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1152\/physrev.00016.2011","volume":"93","author":"HH Versteeg","year":"2013","unstructured":"Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327\u201358.","journal-title":"Physiol Rev"},{"key":"8205_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","volume":"23","author":"P Blair","year":"2009","unstructured":"Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23:177\u201389.","journal-title":"Blood Rev"},{"key":"8205_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1126\/science.134.3483.946","volume":"134","author":"AB Chandler","year":"1961","unstructured":"Chandler AB, Hand RA. Phagocytized platelets: a source of lipids in human thrombi and atherosclerotic plaques. Science. 1961;134:946\u20137.","journal-title":"Science"},{"key":"8205_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nm1760","volume":"14","author":"PK Grewal","year":"2008","unstructured":"Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14:648\u201355.","journal-title":"Nat Med"},{"key":"8205_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood-2007-09-113837","volume":"111","author":"JE Italiano","year":"2008","unstructured":"Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111:1227\u201333.","journal-title":"Blood"},{"key":"8205_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2005.12.005","volume":"238","author":"BD Elzey","year":"2005","unstructured":"Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005;238:1\u20139.","journal-title":"Cell Immunol"},{"key":"8205_CR8","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology. 2015;29:282\u201394.","journal-title":"Oncology"},{"key":"8205_CR9","unstructured":"Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al. Essentials of glycobiology. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2009."},{"key":"8205_CR10","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/S0049-3848(16)30370-X","volume":"141","author":"KM Hoffmeister","year":"2016","unstructured":"Hoffmeister KM, Falet H. Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance. Thromb Res. 2016;141:S68\u201372.","journal-title":"Thromb Res"},{"key":"8205_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3770","volume":"21","author":"R Grozovsky","year":"2015","unstructured":"Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015;21:47\u201354.","journal-title":"Nat Med"},{"key":"8205_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ejphar.2018.11.014","volume":"842","author":"VYU Glanz","year":"2019","unstructured":"Glanz VYU, Myasoedova VA, Grechko AV, Orekhov AN. Sialidase activity in human pathologies. Eur J Pharmacol. 2019;842:345\u201350.","journal-title":"Eur J Pharmacol"},{"key":"8205_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62203-8","volume":"10","author":"A Minami","year":"2020","unstructured":"Minami A, Fujita Y, Shimba S, Shiratori M, Kaneko YK, Sawatani T, et al. The sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid is a glucose-dependent potentiator of insulin secretion. Sci Rep. 2020;10.5198.","journal-title":"Sci Rep"},{"key":"8205_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1099\/0022-1317-80-1-137","volume":"80","author":"SJ Morris","year":"1999","unstructured":"Morris SJ, Price GE, Barnett JM, Hiscox SA, Smith H, Sweet C. Role of neuraminidase in influenza virus-induced apoptosis. J Gen Virol. 1999;80:137\u201346.","journal-title":"J Gen Virol"},{"key":"8205_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bjh.12757","volume":"165","author":"BT Kile","year":"2014","unstructured":"Kile BT. The role of apoptosis in megakaryocytes and platelets. Br J Haematol. 2014;165:217\u201326.","journal-title":"Br J Haematol"},{"key":"8205_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/09537104.2016.1161739","volume":"27","author":"M Lebois","year":"2016","unstructured":"Lebois M, Josefsson EC. Regulation of platelet lifespan by apoptosis. Platelets. 2016;27:497\u2013504.","journal-title":"Platelets"},{"key":"8205_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8205_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2013","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8205_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097\u2013154.","journal-title":"Cell Death Differ"},{"key":"8205_CR20","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/0008-5472.CAN-22-1337","volume":"83","author":"R Singh","year":"2023","unstructured":"Singh R, Yu S, Osman M, Inde Z, Fraser C, Cleveland AH, et al. Radiation therapy-induced neurocognitive impairment is driven by heightened apoptotic priming in early life and prevented by blocking BAX. Cancer Res. 2023;83:3442\u201361.","journal-title":"Cancer Res."},{"key":"8205_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell"},{"key":"8205_CR22","first-page":"1665","volume":"19","author":"H Wei","year":"2019","unstructured":"Wei H, Harper MT. ABT-737 triggers caspase-dependent inhibition of platelet procoagulant extracellular vesicle release during apoptosis and secondary necrosis in vitro. Thromb Haemost. 2019;19:1665\u201374.","journal-title":"Thromb Haemost"},{"key":"8205_CR23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood.V108.11.1107.1107","volume":"108","author":"AR Shoemaker","year":"2006","unstructured":"Shoemaker AR, Mitten MJ, Adickes J, Oleksijew A, Zhang H, Bauch J, et al. The Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice. Blood. 2006;108:1107.","journal-title":"Blood"},{"key":"8205_CR24","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/jth.13397","volume":"14","author":"M Lebois","year":"2016","unstructured":"Lebois M, Dowling MR, Gangatirkar P, Hodgkin PD, Kile BT, Alexander WS, et al. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling. J Thromb Haemost. 2016;14:1882\u20137.","journal-title":"J Thromb Haemost"},{"key":"8205_CR25","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1111\/febs.13714","volume":"283","author":"KA Sarosiek","year":"2016","unstructured":"Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy with BH3 mimetics: recent successes, current challenges and future promise. FEBS J. 2016;283:3523\u201333.","journal-title":"FEBS J"},{"key":"8205_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.drup.2007.08.002","volume":"10","author":"L Zhang","year":"2007","unstructured":"Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat. 2007;10:207\u201317.","journal-title":"Drug Resist Updat"},{"key":"8205_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.trecan.2022.10.004","volume":"9","author":"KA Sarosiek","year":"2023","unstructured":"Sarosiek KA, Wood KC. Endogenous and imposed determinants of apoptotic vulnerabilities in cancer. Trends Cancer. 2023;9:96\u2013110.","journal-title":"Trends Cancer"},{"key":"8205_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10428194.2020.1845332","volume":"62","author":"S de Vos","year":"2021","unstructured":"de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021;62:810\u20138.","journal-title":"Leuk Lymphoma"},{"key":"8205_CR29","doi-asserted-by":"publisher","first-page":"20292","DOI":"10.1074\/jbc.270.35.20292","volume":"270","author":"N Sphyris","year":"1995","unstructured":"Sphyris N, Lord JM, Wales R, Roberts LM. Mutational analysis of the Ricinus Lectin B-chains: GALACTOSE-BINDING ABILITY OF THE 2\u03b3 SUBDOMAIN OF RICINUS COMMUNIS AGGLUTININ B-CHAIN (\u2217). J Biol Chem. 1995;270:20292\u20137.","journal-title":"J Biol Chem"},{"key":"8205_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cca.2008.09.018","volume":"399","author":"P Ferroni","year":"2009","unstructured":"Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, et al. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta. 2009;399:88\u201391.","journal-title":"Clin Chim Acta"},{"key":"8205_CR31","doi-asserted-by":"publisher","first-page":"13657","DOI":"10.1073\/pnas.1515464112","volume":"112","author":"WH Yang","year":"2015","unstructured":"Yang WH, Aziz PV, Heithoff DM, Mahan MJ, Smith JW, Marth JD. An intrinsic mechanism of secreted protein aging and turnover. Proc Natl Acad Sci USA. 2015;112:13657\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8205_CR32","doi-asserted-by":"crossref","unstructured":"Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. In Methods in molecular biology. Springer Nature Protocols, 2019.p. 61\u201376.","DOI":"10.1007\/978-1-4939-8861-7_4"},{"key":"8205_CR33","doi-asserted-by":"crossref","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;0. http:\/\/www.degruyter.com\/view\/j\/bchm.just-accepted\/hsz-2016-0107\/hsz-2016-0107.xml.","DOI":"10.1515\/hsz-2016-0107"},{"key":"8205_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn6579","volume":"8","author":"JKE Spetz","year":"2022","unstructured":"Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, et al. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. Sci Adv. 2022;8.eabn6579.","journal-title":"Sci Adv"},{"key":"8205_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abf8609","volume":"7","author":"Z Inde","year":"2021","unstructured":"Inde Z, Croker BA, Yapp C, Joshi GN, Spetz J, Fraser C, et al. Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. Sci Adv. 2021;7:1\u201318.","journal-title":"Sci Adv"},{"key":"8205_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33461-z","volume":"13","author":"CS Fraser","year":"2022","unstructured":"Fraser CS, Spetz JKE, Qin X, Presser A, Choiniere J, Li C, et al. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022;13. 5789.","journal-title":"Nat Commun"},{"key":"8205_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ccell.2016.11.011","volume":"31","author":"KA Sarosiek","year":"2017","unstructured":"Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell. 2017;31:142\u201356.","journal-title":"Cancer Cell"},{"key":"8205_CR38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129\u201333.","journal-title":"Science"},{"key":"8205_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.molcel.2013.08.048","volume":"51","author":"KA Sarosiek","year":"2013","unstructured":"Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 2013;51:751\u201365.","journal-title":"Mol Cell"},{"key":"8205_CR40","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1021\/cb500340w","volume":"9","author":"GW Foight","year":"2014","unstructured":"Foight GW, Ryan JA, Gull\u00e1 SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014;9:1962\u20138.","journal-title":"ACS Chem Biol"},{"key":"8205_CR41","doi-asserted-by":"crossref","unstructured":"Giannini S, Falet H, Hoffmeister K. 4 - platelet glycobiology and the control of platelet function and lifespan. Platelets. 2019,79\u201397. https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128134566000047.","DOI":"10.1016\/B978-0-12-813456-6.00004-7"},{"key":"8205_CR42","doi-asserted-by":"publisher","first-page":"10042","DOI":"10.1073\/pnas.142005099","volume":"99","author":"LG Ellies","year":"2002","unstructured":"Ellies LG, Ditto D, Levy GG, Wahrenbrock M, Ginsburg D, Varki A, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002;99:10042\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8205_CR43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2014-07-588590","volume":"125","author":"N Mondal","year":"2015","unstructured":"Mondal N, Buffone JrA, Stolfa G, Antonopoulos A, Lau JT, Haslam SM, et al. ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes. Blood. 2015;125:687\u201396.","journal-title":"Blood"},{"key":"8205_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.V128.22.413.413","volume":"128","author":"M Stolla","year":"2016","unstructured":"Stolla M, Grozovsky R, Lee-Sundlov MM, Falet H, Hoffmeister KM. Effects of platelet circulatory age on platelet function. Blood. 2016;128:413.","journal-title":"Blood"},{"key":"8205_CR45","unstructured":"ResearchGate. Bcl-2 and Bcl-xL proteins in non-bleeder versus bleeder platelets. https:\/\/www.researchgate.net\/figure\/Bcl-2-and-Bcl-xL-proteins-in-non-bleeder-versus-bleeder-platelets-at-baseline-and_fig4_315650360."},{"key":"8205_CR46","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1182\/blood-2011-12-398834","volume":"119","author":"M Debrincat","year":"2012","unstructured":"Debrincat M, Josefsson E, James C, Henley K, Ellis S, Lebois M, et al. Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood. 2012;119:5850\u20138.","journal-title":"Blood"},{"key":"8205_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"8205_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/(SICI)1097-0282(199807)46:1<39::AID-BIP4>3.0.CO;2-Z","volume":"46","author":"J Nygren","year":"1998","unstructured":"Nygren J, Svanvik N, Kubista M. The interactions between the fluorescent dye thiazole orange and DNA. Biopolymers. 1998;46:39\u201351.","journal-title":"Biopolymers"},{"key":"8205_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/blood.V75.1.116.116","volume":"75","author":"J Kienast","year":"1990","unstructured":"Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood. 1990;75:116\u201321.","journal-title":"Blood"},{"key":"8205_CR50","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1084\/jem.20110750","volume":"208","author":"EC Josefsson","year":"2011","unstructured":"Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011;208:2017\u201331.","journal-title":"J Exp Med"},{"key":"8205_CR51","unstructured":"Full article: a review of romiplostim mechanism of action and clinical applicability. https:\/\/www.tandfonline.com\/doi\/full\/10.2147\/DDDT.S299591."},{"key":"8205_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105458","volume":"25","author":"MC McNamara","year":"2022","unstructured":"McNamara MC, Hosios AM, Torrence ME, Zhao T, Fraser C, Wilkinson M, et al. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience. 2022;25.105458.","journal-title":"iScience"},{"key":"8205_CR53","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","volume":"20","author":"S Suryani","year":"2014","unstructured":"Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20:4520\u201331.","journal-title":"Clin Cancer Res"},{"key":"8205_CR54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"8205_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"8205_CR56","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.devcel.2024.06.018","volume":"59","author":"JEL Marca","year":"2024","unstructured":"Marca JEL, Kelly GL, Strasser A, Diepstraten ST. Don\u2019t fear the reaper: The role of regulated cell death in tumorigenesis and BH3-mimetics for cancer therapy. Dev Cell. 2024;59:2532\u201348.","journal-title":"Dev Cell"},{"key":"8205_CR57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler M, Braun Y, Smith VM, Westhoff MA, Pereira RS, Pieper NM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Sig Transduct Target Ther. 2025;10:91.","journal-title":"Sig Transduct Target Ther"},{"key":"8205_CR58","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1200\/jco.2009.27.15_suppl.3505","volume":"27","author":"AW Roberts","year":"2009","unstructured":"Roberts AW, Wilson W, Gandhi L, O\u2019Connor OA, Rudin CM, Brown JR, et al. Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. JCO. 2009;27:3505\u20133505.","journal-title":"JCO"},{"key":"8205_CR59","doi-asserted-by":"publisher","first-page":"11108","DOI":"10.1128\/JVI.74.23.11108-11114.2000","volume":"74","author":"O Greengard","year":"2000","unstructured":"Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. The Anti-Influenza Virus Agent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol. 2000;74:11108\u201314.","journal-title":"J Virol"},{"key":"8205_CR60","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3324\/haematol.2016.153668","volume":"101","author":"H Raslova","year":"2016","unstructured":"Raslova H, Vainchenker W, Plo I. Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica. 2016;101:1443\u20135.","journal-title":"Haematologica"},{"key":"8205_CR61","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"8205_CR62","doi-asserted-by":"crossref","unstructured":"Qin X, Presser A, Johnson L, Matoba Y, Shay BS, Xu W, et al. Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance. Preprint at bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2025.06.24.661170v1.full 2025.","DOI":"10.1101\/2025.06.24.661170"},{"key":"8205_CR63","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826\u201333.","journal-title":"Leuk Lymphoma"},{"key":"8205_CR64","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leukemia Lymphoma. 2017;58:2026\u201339.","journal-title":"Leukemia Lymphoma"},{"key":"8205_CR65","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","volume":"24","author":"MS Davids","year":"2018","unstructured":"Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24:4371\u20139.","journal-title":"Clin Cancer Res"},{"key":"8205_CR66","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1074\/jbc.M610643200","volume":"282","author":"KW Adams","year":"2007","unstructured":"Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem. 2007;282:6192\u2013200.","journal-title":"J Biol Chem"},{"key":"8205_CR67","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.3390\/ijms22083999","volume":"22","author":"AEH El-Kadiry","year":"2021","unstructured":"El-Kadiry AEH, Merhi Y. The role of the proteasome in platelet function. Int J Mol Sci. 2021;22:3999.","journal-title":"Int J Mol Sci"},{"key":"8205_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09537109109005496","volume":"2","author":"M Crook","year":"1991","unstructured":"Crook M. Sialic acid: its importance to platelet function in health and disease. Platelets. 1991;2:1\u201310.","journal-title":"Platelets"},{"key":"8205_CR69","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood-2009-01-199414","volume":"114","author":"AL S\u00f8rensen","year":"2009","unstructured":"S\u00f8rensen AL, Rumjantseva V, Nayeb-Hashemi S, Clausen H, Hartwig JH, Wandall HH, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009;114:1645\u201354.","journal-title":"Blood"},{"key":"8205_CR70","doi-asserted-by":"publisher","first-page":"e241895","DOI":"10.1136\/bcr-2021-241895","volume":"14","author":"Y Maeda","year":"2021","unstructured":"Maeda Y, Yamamoto D, Tamai Y. Eltrombopag-induced recurrent stroke in idiopathic thrombocytopenic purpura. BMJ Case Rep. 2021;14:e241895.","journal-title":"BMJ Case Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08205-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:04:45Z","timestamp":1767884685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08205-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8205"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08205-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"5 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}